Despite numerous positive pre-clinical data proving the beneficial outcome of IL-6 targeting in PDAC, the complete lack of IL-6 in the TME of PDAC had surprisingly no significant impact on the development of pancreatic cancer in mouse models. This evidence concerns the gene IL6 and familial pancreatic carcinoma.